Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

In the near future, oncologists should be able to identify and manage cardiac risks, both in clinical trials and daily practice. Many successful agents – including anthracyclines and trastuzumab ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Figure 1: Key signaling pathways and targeted factors ... several major pathways involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch, NF-κB, and ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

This two-pronged attack hits an essential signaling pathway that drives ... in a common form of breast cancer, called hormone-receptor-positive (HR-positive), HER2-negative breast cancer.

Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast ... therapy in patients that have alterations in ...

Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant ...

The review highlights how certain gene mutations and disrupted signaling pathways influence ... involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch ...